Navigation Links
Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
Date:5/7/2012

LOS ANGELES, May 7, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions. 

"The Company intends to pursue alternative financing under more favorable conditions", stated Anthony Cataldo, President & Chief Executive Officer of Genesis Biopharma, Inc. 

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers.  The company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma.  Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date.  The company does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
2. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
3. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
4. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
5. Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
6. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
7. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
8. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
9. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
10. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
11. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... ... ChenMed , a leading provider of value-based care for seniors, today announced ... Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine at the ... for the UVA Health System, brings 30 years of highly relevant experience to his ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced ... its existing adherence automation lines. The ATP® Mini and InspectRx® Mini ... TCG’s standard products, but at a size and price point that can help ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):